The global bioelectric medicine market size is expected to reach USD 35.42 billion by 2030, registering a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market include the rising geriatric population, strategic initiatives by key companies, and increasing investment in R&D for advanced electroceuticals/ bioelectric medicines. In April 2022, Cochlear agreed to acquire Demant's hearing implants business - Oticon Medical. This would enable the company to increase its R&D investments and market growth activities and provide it with greater scale.
In 2021, around 20.8% or more than one-fifth of the population in the EU was aged 65 and over, according to Eurostat. The aging population is prone to medical disorders such as Alzheimer's disease, epilepsy, cardiac arrhythmias, Parkinson's disease, and depression. Hence, this is a key factor contributing to the market growth. Advanced bioelectronic devices including cochlear implants, implantable cardioverter defibrillators, cardiac pacemakers, and spinal cord stimulators are used for the treatment of these conditions.
Growing investments in the R&D of advanced electroceuticals is another major factor supporting the growth of the market. For example, in 2021, Medtronic invested around USD 2.5 billion in R&D for the development of advanced products. According to ElectroCore, almost 325,000 people in the U.S. experience cluster headaches every year. The company capitalized on the opportunity by developing a product called gammaCore, which received FDA clearance in 2018. The product is indicated for non-invasive VNS therapy helpful in managing painful headaches in adults.
Request a free sample copy or view the report summary: Bioelectric Medicine Market Report
By product, the implantable cardioverter defibrillators segment was the largest revenue-generating segment in 2022 owing to the wider application of these products in the treatment of arrhythmia and CHF
The implantable electroceutical devices type segment accounted for the largest revenue share in 2022 owing to technological advancements
In the application segment, the arrhythmia segment accounted for the largest share in 2022 and is expected to remain dominant throughout the forecast period
The hospital end-user segment dominated the market in 2022 due to the escalating number of electroceutical device implant procedures in hospitals
The North American market accounted for the largest revenue share in 2022 mainly due to a large number of medical devices companies in this region
The Asia Pacific region is expected to register the fastest growth rate over the forecast period. The developing healthcare infrastructure and rising healthcare awareness in Asian countries such as China and India are major factors contributing to the growth of this regional market
Grand View Research has segmented the global bioelectric medicine market based on product, type, application, end-use, and region:
Bioelectric Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)
Implantable Cardioverter Defibrillators
Cardiac Pacemakers
Cochlear Implants
Spinal Cord Stimulators
Deep Brain Stimulators
Transcutaneous Electrical Nerve Stimulators
Sacral Nerve Stimulators
Vagus Nerve Stimulators
Other
Bioelectric Medicine Type Outlook (Revenue, USD Million, 2018 - 2030)
Implantable Electroceutical Devices
Non-invasive Electroceutical Devices
Bioelectric Medicine Application Outlook (Revenue, USD Million, 2018 - 2030)
Arrhythmia
Pain Management
Sensorineural Hearing Loss
Parkinson’s Disease
Tremor
Depression
Treatment-resistant Depression
Epilepsy
Urinary and Fecal Incontinence
Others
Bioelectric Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Others
Bioelectric Medicine Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
List of Key Players in the Bioelectric Medicine Market
Medtronic
Abbott
Boston Scientific Corporation
Cochlear Ltd.
LivaNova PLC
Biotronik SE & Co KG
electroCore, Inc.
Sonova
Nevro Corp.
Stimwave LLC
"The quality of research they have done for us has been excellent..."